About me
Jennifer Michaelson is a biotech executive with 20+ years of industry experience in oncology, immunology, and immune-oncology drug development. Prior to joining Cullinan Therapeutics, Jennifer participated in the launch of Jounce Therapeutics, where she built and led multiple departments, including Tumor Immunology, Pharmacology, and Preclinical Development, and went on to serve as the Executive Program Leader for the lead program, JTX-2011. Jennifer’s prior roles in industry include a 10-year tenure at Biogen, where she served as project leader for several monoclonal antibody and bispecific antibody programs in both the oncology and immunology therapeutic areas. Jennifer has also served as a consultant at Third Rock Ventures for multiple stealth stage immune-oncology companies.
Jennifer earned her B.A. in Biology from Princeton University and Ph.D. from the Department of Cell Biology at Albert Einstein College of Medicine, and she completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School
